Anti-Infective Drugs Market to Hit USD 177.9 billion by 2031 | Transparency Market Research Inc.

Growth in government funding to enhance drug approvals is also boosting the anti-infective drugs market revenue, and increases in R&D and technological advancements are augmenting the market.


Wilmington, Delaware, United States, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global anti-infective drugs market is projected to flourish at a CAGR of 4.0% from 2023 to 2031. As per the report published by TMR, a valuation of US$   117.9 billion is anticipated for the market in 2031. As of 2023, the demand for anti-infective drugs is expected to close at US$   billion.

The global aging population is more susceptible to infections, as the elderly tend to have weaker immune systems. As the population ages, the demand for anti-infective drugs to treat and prevent infections in this demographic is expected to grow. The rise of antibiotic-resistant bacteria and superbugs has created a pressing need to develop new antibiotics and anti-infective drugs. This has spurred investment and innovation in the market.

With the growing countries' investment in healthcare infrastructure and R&D, there is more significant support for the development and availability of anti-infective drugs. Increased healthcare spending can boost the market's growth. The growing public awareness campaigns and education about the importance of infection prevention and treatment have increased the demand for anti-infective drugs.

Governments and regulatory agencies around the world often provide incentives, grants, and regulatory support for the development of new anti-infective drugs. These initiatives can promote market growth.

Download Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41204

Competitive Landscape

The global landscape is consolidated, with the presence of several key players that control the majority of the market share. According to the anti-infective drugs market research, leading companies focus on mergers & acquisitions, new product development, and product portfolio expansion to gain incremental opportunities.

  • Pfizer Inc.
  • Gland Pharma Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Abbott
  • Astellas Pharma Inc.
  • Alkem Laboratories
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited Sanofi

Key Takeaways from the Market Study

  • As of 2022, the anti-infective drugs market was valued at US$ 139.1 billion
  • Based on drug class, the antivirals drug class segment is anticipated to dominate the global market during the forecast period, owing to the rise in prevalence of new infectious diseases.
  • Based on Distribution Channel, the retail pharmacies distribution channel segment is anticipated to lead the global industry during the forecast period.

Anti-Infective Drugs Market: Key Trends and Opportunistic Frontiers

  • Growth in government initiatives to create awareness about infectious diseases and their treatment options is a key factor fueling the anti-infective drugs market expansion.
  • The adoption of telemedicine and digital health solutions has made it easier for patients to access healthcare services, including anti-infective drug prescriptions and monitoring, which can contribute to market growth.
  • The growing middle-class population in developing countries, coupled with improved access to healthcare, is expanding the market for anti-infective drugs.
  • Pharmaceutical companies and research institutions are investing in the development of novel anti-infective drugs and therapies. This ongoing research and development activity drives innovation in the field.

 

Request for Custom Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=41204

Anti-Infective Drugs Market – Regional Analysis

  • North America accounted for the largest share of the global market in 2022.  The market in North America is driven by a high burden of infectious diseases, especially in the United States, and significant R&D investments in anti-infective drugs. Pharmaceutical companies in the United States are major players in the global anti-infective drugs market.
  • Asia-Pacific has a growing market for anti-infective drugs due to large populations and increasing healthcare expenditure.
  • Countries such as China and India are hubs for generic drug manufacturing and are contributing to the production of affordable anti-infective drugs. The prevalence of infectious diseases and the development of new healthcare infrastructure are key growth factors.

Key Developments in the Anti-Infective Drugs Market

  • Pfizer Inc. is a global pharmaceutical giant known for its contributions to developing anti-infective drugs. It has a long history of producing antibiotics and antiviral drugs, including Zithromax (azithromycin) and Prevnar (pneumococcal vaccine).
  • GlaxoSmithKline is a major player in the anti-infective drugs market, focusing on vaccines and medicines for infectious diseases. They are known for vaccines like Shingrix, as well as antiviral drugs like ViiV Healthcare's HIV treatments.
  • Merck & Co., Inc. is a leading pharmaceutical company with a strong portfolio of anti-infective drugs. They are known for antiviral drugs like Isentress and vaccines like Gardasil.

Anti-Infective Drugs Market – Key Segments

Drug Class

  • Antibacterials
  • B-lactams
  • Quinolones
  • Macrolides
  • Tetracycline
  • Aminoglycoside
  • Others (Phenicols, Sulfonamides, etc.)
  • Antivirals
  • Miscellaneous Antivirals
  • Adamantane Antivirals
  • Antiviral Boosters
  • Others (Antiviral Combinations, Antiviral Interferons, etc.)
  • Antifungals
  • Azoles
  • Echinocandins
  • Polyenes
  • Others
  • Others (Antiparasitics, Anthelmintics, etc.)

Route of Administration

  • Oral
  • Parenteral
  • Others (Topical, etc.)

Indication

  • Pneumonia
  • Sepsis
  • Tuberculosis
  • Influenza
  • HIV Infection
  • Hepatitis Virus Infection
  • Respiratory Virus Infection
  • Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

 Contact us for Special Discount and Pricing -  

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=41204

 About Transparency Market Research

 Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

 Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

 Contact:

 Nikhil Sawlani

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Blog: https://tmrblog.com   

Email: sales@transparencymarketresearch.com